Purdue Pharma teams up with Alivio Therapeutics to advance ALV-107
Category: #health  By Mateen Dalal  Date: 2019-01-28
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Purdue Pharma teams up with Alivio Therapeutics to advance ALV-107

Purdue Pharma L.P., the Connecticut-based pharmaceutical company, has reportedly announced that it has signed a partnership agreement with Alivio Therapeutics to advance one of its product candidates via clinical development.

As per trusted sources, Purdue Pharma would have an option to invest in the next equity financing of Alivio Therapeutics. Reportedly, Alivio is eligible to receive royalties on product sales and more than USD 260 million in R&D milestones. Moreover, the firm is also slated to be paid up to USD 14.75 million in upfront and near-term license exercise payments.

President and Chief Executive Officer of Purdue Pharma, Craig Landau M.D., was reportedly quoted saying that the latest partnership is a significant milestone in the company’s continued pursuit of non-opioid treatments for pain and underscores a major step to further diversify product portfolio. Purdue Pharma is impressed with the innovative platform technology of Alivio as it focuses on meeting the patient needs, especially in regions where very few treatment options are available, Landau further added.

For the record, ALV-107 is a non-opioid treatment presently being developed for interstitial cystitis/bladder pain syndrome. Sources familiar with the development claim that the ALV-107 program recently secured a USD 3.3 million U.S. Department of Defense (DoD) Technology/Therapeutic Development Award. The funds would be utilized to back the preclinical R&D activities, including GMP manufacturing and ensure the filing of an investigational new drug (IND) application.

Chief Innovation Officer of PureTech and a Co-founder of Alivio Therapeutics, Eric Elenko, PhD, reportedly commented that the company is delighted to forge the new collaboration aimed at advancing ALV-07 for the potential treatment of interstitial cystitis/bladder pain syndrome. Alivio is swiftly progressing its potential application across inflammatory bowel and pouchitis disease as part of its internal R&D lab.

Moreover, the platform technology of the firm has been created to resolve numerous inflammatory conditions and the non-opioid approach may provide a unique novel treatment option for an ailment where there is a humongous unmet need, Elenko further added.

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

General Motors to recoup USD 1.9 Bn from LG spent on Bolt EV recall

General Motors to recoup USD 1.9 Bn from LG spent on Bolt EV recall

By Mateen Dalal

GM will recover almost all the costs from the recall of its Bolt EV models. Despite the EV battery manufacturing mishap from LG, the two companies will continue to work together. General Motors (GM) has agreed to recover around USD 1.9 billion f...

Tata Motors records 25% jump in global sales in second quarter of 2021

Tata Motors records 25% jump in global sales in second quarter of 2021

By Mateen Dalal

The automaker’s annual wholesale growth has been around 24%. The company saw a 10% rise in passenger car sales during Q2 2021, as compared to the same period in 2020. Tata Motors Limited reported substantial growth in Q2 2021, with its glo...

Carbon Budgets for corporate business travels to hit airlines: Report

Carbon Budgets for corporate business travels to hit airlines: Report

By Mateen Dalal

With major companies considering ways to reduce carbon emissions from corporate travel, airlines are preparing for a setback in business-class travel, which is an important revenue driver according to industry experts and executives. The airline ind...